Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Myelodysplastic Syndrome.

INR:3550. the daily life of the immortal king season 5 release date Breaking news! Chinese scientists reveal the mechani ...

Cytokine release syndrome (CRS) developed in all patients, including grade 3/4 events in nearly half. "Bicistronic CD19/CD22-targeted CAR T-cell therapy is a safe and effective regimen which ...

The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

This study is an open-label, dose-escalation/expansion Phase I clinical trial (NCT05920876), aiming to assess the safety of ...

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...